Evidence map›Paper›PMID 30237823›Full record

ArticleAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2018

Preliminary study on chronic granulomatous disease in Sri Lanka.

Shalinda Jude Arjuna Fernando, Noorul Mifra Faiz, Shiroma Mangaika Handunnetti, Aruna Dharshan De Silva, Wasala Mudiyanselage Dhanushka Kumari Dasanayake, Geethani Devika Wickramasinghe, Rathnayake Mudiyanselage Chandima Hasanthi Karunatilake, Nilhan Rajiva de Silva

Open access · goldAbstract read
In one paragraph

Article in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Clinical and demographic pattern of chronic granulomatous disease (CGD) from a multicenter perspective: Malaysia's experience over 26 years.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2021
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Shalinda Jude Arjuna Fernando1Institute of Biochemistry, Molecular Biology & Biotechnology (IBMBB), University of Colombo, Colombo 03, Sri Lanka.ORCID 0000-0001-6652-5406
Noorul Mifra Faiz1Institute of Biochemistry, Molecular Biology & Biotechnology (IBMBB), University of Colombo, Colombo 03, Sri Lanka.
Shiroma Mangaika Handunnetti1Institute of Biochemistry, Molecular Biology & Biotechnology (IBMBB), University of Colombo, Colombo 03, Sri Lanka.
Aruna Dharshan De Silva2Genetech Research Institute, Colombo 08, Sri Lanka.
Wasala Mudiyanselage Dhanushka Kumari Dasanayake3Department of Immunology, Medical Research Institute (MRI), Colombo 08, Sri Lanka.
Geethani Devika Wickramasinghe3Department of Immunology, Medical Research Institute (MRI), Colombo 08, Sri Lanka.
Rathnayake Mudiyanselage Chandima Hasanthi Karunatilake3Department of Immunology, Medical Research Institute (MRI), Colombo 08, Sri Lanka.
Nilhan Rajiva de Silva3Department of Immunology, Medical Research Institute (MRI), Colombo 08, Sri Lanka.
Medical Research Institute · LKUniversity of Colombo · LKGenetech (Sri Lanka) · LK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChronic granulomatous disease (CGD) is a rare primary immunodeficiency of the phagocytic cells, which results in absent or diminished levels of microbicidal reactive oxygen species. The disease occurs due to germline mutations in the genes encoding the five subunits of NADPH oxidase complex. The present study is a pilot study to understand the clinical and genetic aspects of CGD in Sri Lanka.

methodsClinical records of thirteen CGD patients were analysed and compared with similar studies performed in different countries and regions to identify patterns in demographics, clinical manifestations and infectious agents. Genomic DNA and cDNA were analysed in eight patients to identify mutations in

resultsThe onset of symptoms in the patient cohort was very early (mean 4.6 months) compared to 20 months in India and 23.9 months in Latin America. Similarly, the age at diagnosis was lower (mean 1.6 years after birth) compared to other studies; 4.5 years in India and 6.1 years in Europe. Pulmonary manifestations were the most common (85%), followed by skin/subcutaneous infections (77%) and lymphadenopathy (62%). The death rate of local patients (38%) was higher than other countries (India 35%, Europe 20%). Majority (77%) were treated for tuberculosis at some point in life. Genetic analysis confirmed six out of eight patients as X-linked CGD cases with mutations in

conclusionsThe clinical presentation, manifestations and genetic subtypes in the local cohort, appear to be comparable with global trends. Mycobacterial infections should be investigated and treated with more prominence. Effective treatment options are required to control the high mortality rate.

Indexed as

Autosomal recessiveChronic granulomatous diseaseCYBBMycobacterial infectionsNADPH oxidaseNCF1Sri LankaX-linked

Identifiers

PMID30237823
PMCPMC6139906
OpenAlexW2807340648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.